Background: The role of anesthesia as an elicitor of mast cell (MC) mediator release symptoms in mastocytosis is poorly investigated. Objective: To determine the frequency and type of MC mediator release symptoms during anesthetic procedures in mastocytosis patients. Methods: Medical records were reviewed regarding the anesthetic techniques for 501 mastocytosis patients (459 adults and 42 children; 95 and 5% with systemic involvement, respectively) who were subjected to 676 and 50 anesthetic techniques, respectively. General, sedation, epidural, and local anesthetic techniques were used in 66 (10%), 67 (10%), 76 (11%), and 515 (76%) adult patients and in 24 (48%), 8 (16%), 2 (4%), and 25 (50%) pediatric patients. Results: The frequency of perioperative MC mediator-related symptoms and anaphylaxis was 2 and 0.4% in the adult series and 4 and 2% among children. In the adult series, this frequency was significantly higher in patients who previously presented with anaphylaxis (p = 0.03), underwent major surgeries (p < 0.001) and general anesthesia (p = 0.02), and were not given prophylactic antimediator therapy (PAT) 1 h before the anesthesia (H1/H2 antihistamines and benzodiacepines; p = 0.002).Hypersensitivity and/or allergy to the involved drugs and latex allergy were ruled out in all but one symptomatic case; when PAT was given and sedation was added, some cases later tolerated the same anesthetic drugs. Conclusion: The frequency of perioperative anaphylaxis appears to be higher in mastocytosis patients than in the general population. Mastocytosis should not be a contraindication for anesthesia since PAT and adequate anesthetic management using the drugs with the safest profile appears to be effective in preventing/controlling MC mediator-associated symptoms.

Keywords:
Anesthesia, Anaphylaxis, Mast cell mediator release-associated symptoms, Mastocytosis
1.
Escribano L, Alvarez-Twose I, Sanchez-Munoz L, Garcia-Montero A, Nunez R, Almeida J, et al: Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009;124:514-521.
2.
Matito A, Morgado JM, Alvarez-Twose I, Sanchez-Muñoz L, Pedreira CE, Jara-Acevedo M, Teodosio C, et al: Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome. PLoS One 2013;8:76116e.
3.
Gonzalez de Olano D, de la Hoz B, Nunez-Lopez R, Sanchez-Munoz L, Cuevas M, Dieguez C, et al: Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy 2007;37:1547-1555.
4.
Brockow K, Jofer C, Behrendt H, Ring J: Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008;63:226-232.
5.
Marone G, Stellato C: Activation of human mast cells and basophils by general anaesthetic drugs. Monogr Allergy 1992;30:54-73.
6.
Stellato C, Marone G: Mast cells and basophils in adverse reactions to drugs used during general anesthesia. Chem Immunol 1995;62:108-131.
7.
Alvarez-Twose I, Morgado JM, Sanchez-Munoz L, Garcia-Montero A, Mollejo M, Orfao A, et al: Current state of biology and diagnosis of clonal mast cell diseases in adults. Int J Lab Hematol 2012;34:446-460.
8.
Escribano L, Akin C, Castells M, Orfao A, Metcalfe D: Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 2002;81:677-690.
9.
Stellato C, De Paulis A, Cirillo R, Mastronardi P, Mazzarella B, Marone G: Heterogeneity of human mast cells and basophils in response to muscle relaxants. Anesthesiology 1991;74:1078-1086.
10.
Carter MC, Uzzaman A, Scott LM, Metcalfe DD, Quezado Z: Pediatric mastocytosis: routine anesthetic management for a complex disease. Anesth Analg 2008;107:422-427.
11.
Dewachter P, Castells MC, Hepner DL, Mouton-Faivre C: Perioperative management of patients with mastocytosis. Anesthesiology 2014;120:753-759.
12.
James PD, Krafchik BR, Johnston AE: Cutaneous mastocytosis in children: anaesthetic considerations. Can J Anaesth 1987;34:522-524.
13.
Ahmad N, Evans P, Lloyd-Thomas AR: Anesthesia in children with mastocytosis - a case based review. Paediatr Anaesth 2009;19:97-107.
14.
Matito A, Alvarez-Twose I, Sanchez-Munoz L, Manzanero M, Escribano L: Frequency of mast cells-mediator related symptoms during anesthesia in patients with mastocytosis: a retrospective study in 148 risk procedures with anesthesia by the Spanish Network on Mastocytosis (REMA). Allergy 2010;65:S345-S346.
15.
Coleman MA, Liberthson RR, Crone RK, Levine FH: General anesthesia in a child with urticaria pigmentosa. Anesth Analg 1980;59:704-706.
16.
Scott HW Jr, Parris WC, Sandidge PC, Oates JA, Roberts LJ: Hazards in operative management of patients with systemic mastocytosis. Ann Surg 1983;197:507-514.
17.
Hosking MP, Warner MA: Sudden intraoperative hypotension in a patient with asymptomatic urticaria pigmentosa. Anesth Analg 1987;66:344-346.
18.
Smith GB, Gusberg RJ, Jordan RH, Kim B: Histamine levels and cardiovascular responses during splenectomy and splenorenal shunt formation in a patient with systemic mastocytosis. Anaesthesia 1987;42:861-867.
19.
Desborough JP, Taylor I, Hattersley A, Garden A, Wolff A, Bloom SR, et al: Massive histamine release in a patient with systemic mastocytosis. Br J Anaesth 1990;65:833-836.
20.
Greenblatt EP, Chen L: Urticaria pigmentosa: an anesthetic challenge. J Clin Anesth 1990;2:108-115.
21.
Ojeda A, Crespo A, Crespo V, Sánchez F, Sanz A, Vera A: Telangiectasia maculosa eruptiva persistente con afectación sistémica y evolución postoperatoria fatal. Actas Dermosifiliogr 1996;87:539-542.
22.
Vaughan STA, Jones GN: Systemic mastocytosis presenting as profound cardiovascular collapse during anaesthesia. Anaesthesia 1998;53:804-807.
23.
Tirel O, Chaumont A, Ecoffey C: Circulatory arrest in the course of anesthesia for a child with mastocytosis. Ann Fr Anesth Reanim 2001;20:874-875.
24.
Brodier C, Guyot E, Palot M, David P, Rendoing J: Anesthesia of a child with a cutaneous mastocytosis. Cah Anesthesiol 1993;41:77-79.
25.
Bridgman DE, Clarke R, Sadleir PH, Stedmon JJ, Platt P: Systemic mastocytosis presenting as intraoperative anaphylaxis with atypical features: a report of two cases. Anaesth Intensive Care 2013;41:116-121.
26.
Lerno G, Slaats G, Coenen E, Herregods L, Rolly G: Anaesthetic management of systemic mastocytosis. Br J Anaesth 1990;65:254-257.
27.
Yaniv R, Segal E, Perel A: Anesthetic considerations in mast-cell proliferative disease (urticaria pigmentosa and mastocytosis). Harefuah 1992;122:780-784.
28.
Chaar CI, Bell RL, Duffy TP, Duffy AJ: Guidelines for safe surgery in patients with systemic mastocytosis. Am Surg 2009;75:74-80.
29.
Dewachter P, Mouton-Faivre C, Cazalaa JB, Carli P, Lortholary O, Hermine O: Mastocytosis and anaesthesia. Ann Fr Anesth Reanim 2009;28:61-73.
30.
Konrad FM, Schroeder TH: Anaesthesia in patients with mastocytosis. Acta Anaesthesiol Scand 2009;53:270-271.
31.
Calvo N, Telletxea S, Intxaurraga K, Arizaga A: Systemic mastocytosis and perioperative management: a report of 2 cases. Rev Esp Anestesiol Reanim 2010;57:192-194.
32.
Brockow K, Bonadonna P: Drug allergy in mast cell disease. Curr Opin Allergy Clin Immunol 2012;12:354-360.
33.
Delalande JP, Rea D, Fenoll B: Absence of mast cell degranulation during general anesthesia in a child with mastocytosis. Ann Fr Anesth Reanim 1992;11:393-394.
34.
Koitabashi T, Takino Y: Anesthetic management of a patient with urticaria pigmentosa. Masui 1995;44:279-281.
35.
Borgeat A, Ruetsch YA: Anesthesia in a patient with malignant systemic mastocytosis using a total intravenous anesthetic technique. Anesth Analg 1998;86:442-444.
36.
Auvray L, Letourneau B, Freysz M: Mastocytosis: general anesthesia with remifentanil and sevoflurane. Ann Fr Anesth Reanim 2001;20:635-638.
37.
Fisher MM, Baldo BA: Mast cell tryptase in anaesthetic anaphylactoid reactions. Br J Anaesth 1998;80:26-29.
38.
Lorenzi P, Filoni M, Manetta G, Bonechi ML, Salvati G, Tanini A: Anaphylactic reaction to thiopental: a case documented by tryptase values and RAST. Minerva Anestesiol 1999;65:659-663.
39.
Valent P, Horny HP, Li CY, Longley BJ, Metcalfe DD, Parwaresch MR, et al: Mastocytosis (mast cell disease); in Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): WHO Classification of Tumours: Pathology and Genetics - Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001, vol 1, pp 291-302.
40.
Valent P, Horny HP, Escribano L, Longley-BJ J, Li CL, Schwartz LB, et al: Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603-625.
41.
Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K, et al: Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37:435-453.
42.
Horny HP, Metcalfe DD, Bennet JM, Bain BJ, Akin C, Escribano L, et al: Mastocytosis; in Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC, 2008, pp 54-63.
43.
Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD: A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004;103:3222-3225.
44.
ASA Relative Value Guide. 2013. www.asaqh.org.
45.
Earl R: Definition of major and minor surgery: a question and an answer. Ann Surg 1917;65:799.
46.
Currie M, Webb RK, Williamson JA, Russell WJ, Mackay P: The Australian Incident Monitoring Study: clinical anaphylaxis - an analysis of 2,000 incident reports. Anaesth Intensive Care 1993;21:621-625.
47.
Escolano F, Valero A, Huguet J, Baxarias P, de Molina M, Castro A, et al: Prospective epidemiologic study of perioperative anaphylactoid reactions occurring in Catalonia (1996-7). Rev Esp Anestesiol Reanim 2002;49:286-293.
48.
Kroigaard M, Garvey LH, Gillberg L, Johansson SG, Mosbech H, Florvaag E, et al: Scandinavian Clinical Practice Guidelines on the diagnosis, management and follow-up of anaphylaxis during anaesthesia. Acta Anaesthesiol Scand 2007;51:655-670.
49.
Lieberman P, Nicklas RA, Oppenheimer J, Kemp SF, Lang DM, Bernstein DI, et al: The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010;126:477-480.
50.
Navarro J, Escolano F, Sánchez JC, Mansilla R, Castillo J: Incidence of severe perioperative anaphylactoid reactions. Eur J Anaesthesiol 2003;23:A-26.
51.
Alvarez-Twose I, Vano-Galvan S, Sanchez-Munoz L, Morgado JM, Matito A, Torrelo A, et al: Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis. Allergy 2012;67:813-821.
52.
Bonadonna P, Lombardo C, Zanotti R: Mastocytosis and allergic diseases. J Investig Allergol Clin Immunol 2014;24:288-297.
53.
Bonadonna P, Lombardo C: Drug allergy in mastocytosis. Immunol Allergy Clin North Am 2014;34:397-405.
54.
Matito A, Alvarez-Twose I, Morgado JM, Sanchez-Munoz L, Orfao A, Escribano L: Clinical impact of pregnancy in mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) in 45 cases. Int Arch Allergy Immunol 2011;156:104-111.
55.
Manfredi G, Pezzuto F, Balestrieri A, Lo SM, Montera MC, Pio A, et al: Perioperative anaphylactic risk score for risk-oriented premedication. Transl Med UniSa 2013;7:12-17.
56.
Mertes PM, Malinovsky JM, Jouffroy L, Aberer W, Terreehorst I, Brockow K, et al: Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice. J Investig Allergol Clin Immunol 2011;21:442-453.
57.
Klein NJ, Misseldine S: Anesthetic considerations in pediatric mastocytosis: a review. J Anesth 2013;27:588-598.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.